The strong new pain reliever appears to Adriana the promise to end the dependence on opioid materials

However, in the United States, opium oxygenin was described once, leading to an increase in the misuse of artificial opiates such as fentanel. As a result, the number of deaths caused by an overdose of opioid materials exceeded 80,000 in 2023, as it escalated into a national public health crisis referred to as the “opioid material crisis”.

Opium may be close to a competitor, however. A team of researchers at the University of Kyoto recently discovered a new residence, or a pain reliever, which has an effect through a completely different mechanism. Clinical development of their property Adriana It is currently running as part of an international cooperative effort.

“If it succeeds in marketing successfully, Adriana will provide a new option for pain management that does not depend on opiates, which contributes significantly to reducing the use of opioids in clinical places,” says the opposite author, Massochi Hagwarra, a professor who was particularly brought at Kyoto University.

The research team was first inspired by the materials that mimic NurraderininWhich was released in life -threatening situations α2A-ERERNOETPONORS To suppress the pain. However, these constitute a high risk of instability and blood vessels. After monitoring the levels of Nurdrenaline and α2B-adrenoettorsThe team assumed that the prohibition of α2B-adrenoetors receptors selectively can raise the levels of nordrenaline, which activates the α2a-adrenoetors receptors and leads to relieving pain without causing cardiovascular instability.

To determine selective inhibitors of α2B-Ernoetors receptors and measuring the activity of the individual sub-species of α2-adrenoceptor, researchers used a new technique known as as TGFα sinking the examination He conducted a compound examination, which leads to the discovery of the first anti-α2B-Ernoceptor anti-anti-anti-anti-α2BTTTOR in the world.

After success in managing the boat to mice and conducting non -clinical studies to evaluate their safety, the clinical experiments led by the doctor at Kyoto University Hospital were conducted. Both the first stage experience in healthy volunteers and the experience of the second stage in patients with post -surgery after lung cancer surgery resulted in very promising results.

Based on these results, preparations are now underway to conduct a widely clinical trial in the United States, in cooperation with BTB Therapics, Inc, an adventure company that was established at Kyoto University.

As the first non-opium housing in Japan, Adriana has the capabilities not only to relieve the severe pain of patients all over the world, but it can also play a meaningful role in addressing the opioid material crisis-an urgent social issue in the United States-and thus contribute to international public health efforts.

“We aim to assess the analgesic effects of Adriana across different types of pain, and we ultimately make this treatment within reach of a largest population of patients with chronic pain,” said Haguara.